cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Andri Putra Kesmawan
Contact Email
journal@idpublishing.org
Phone
+6281990251989
Journal Mail Official
journal@idpublishing.org
Editorial Address
Perumahan Sidorejo, Jl. Sidorejo Gg. Sadewa No.D3, Sonopakis Kidul, Ngestiharjo, Kapanewon Kasihan, Kabupaten Bantul, Daerah Istimewa Yogyakarta 55184
Location
Kab. bantul,
Daerah istimewa yogyakarta
INDONESIA
Sciences and Clinical Pharmacy Research Journal
Published by Indonesian Journal Publisher
ISSN : -     EISSN : 30474493     DOI : https://doi.org/10.47134/scpr
Core Subject : Health,
Medicine & Pharmacology
Sciences and Clinical Pharmacy Research Journal is dedicated to the exploration of Pharmaceutical Sciences and Community and Clinical Pharmacy. In the realm of pharmaceutical sciences, the journal welcomes research articles spanning Pharmaceutical Biology and Pharmacognosy, Pharmaceutical Chemistry, pharmaceutics, Pharmacology and Toxicology, as well as Biotechnology. In the domain of Community and Clinical Pharmacy, the journal encompasses discussions on Hospital Pharmacy, Clinical Pharmacy, Pharmacy Management, and Social Pharmacy.
Arjuna Subject : Pharmacology, Toxicology and Pharmaceutics - Ilmu Farmasi
Articles 41 Documents
 1   2   3   4   5 
Re-evaluating Albendazole-Based Preventive Chemotherapy for Soil-Transmitted Helminths in Indonesia: A Narrative Review on Efficacy, Challenges, and Future Strategies Gunasari, Lala; Nurmansyah, Dian; Triana, Dessy
Sciences and Clinical Pharmacy Research Journal Vol. 3 No. 1 (2026): April
Publisher : Indonesian Journal Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.47134/scpr.v3i1.5601

Abstract

This narrative review seeks to critically analyze the efficacy of albendazole, the cornerstone anthelmintic of the program. Relevant literature (2020-2025) was identified through a systematic search of the ScienceDirect and Google Scholar databases. While evidence confirms albendazole's effectiveness, with cure rates up to 93%, its performance is inconsistent and influenced by a confluence of factors. A critical constraint identified is the absence of robust, large-scale national surveillance data on STH prevalence and drug efficacy, hindering a comprehensive assessment of albendazole's performance within the program. The persistent burden of STH underscores a gap between program implementation and its intended public health impact. While albendazole remains essential, its variable efficacy and operational barriers necessitate a critical reassessment of the current strategy.

Page 5 of 5 | Total Record : 41

 1   2   3   4   5 

Filter by Year

2024 2026


Reset
Filter By Issues
All Issue Vol. 3 No. 1 (2026): April Vol. 2 No. 4 (2026): January Vol. 2 No. 3 (2025): October Vol. 2 No. 2 (2025): July Vol. 1 No. 4 (2025): January Vol. 1 No. 3 (2024): October Vol. 1 No. 2 (2024): July Vol. 1 No. 1 (2024): April